William M. Grady
M.D., University of Michigan - Ann Arbor, 1990.
B.S., University of Michigan - Ann Arbor, Biomedical Sciences, 1987.
Molecular and cell biology of gastrointestinal cancer: genetic and epigenetic alterations in cancer
Clinical management of gastrointestinal cancer family syndromes
Colon cancer prevention
Biomarkers for colon cancer prevention
Biomarkers for optimizing management of Barretts esophagus
(Reading, Writing, Speaking)
English: (Fluent, Fluent, Fluent)
American Association for Cancer Research
American Association for the Study of Liver Disease
American College of Gastroenterology
American Gastroenterological Association
Honors and Awards
2009, Member, Society of Clinical Investigation
2008-2013, Burroughs Wellcome Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund, Fred Hutchinson Cancer Research Center
2005-2010, Presidential Early Career Award for Scientists and Engineers (PECASE), Department of Veterans Affairs
2002-2005, Mallinckrodt Scholar Award, 42nd Scholar, Edward Mallinckrodt Jr. Foundation
2002-2007, Damon Runyon-Lilly Clinical Investigator Award, Damon Runyon Cancer Research Foundation
2001, John Walsh Memorial GIDH Award in Basic Research, John Walsh Memorial
1997, ADHF Advanced Research Training Award, ADHF
1993, Outstanding Senior Resident Award, University of Michigan
American Society of Clinical Investigation Member, American Society of Clinical Investigation
2000-2004, Assistant Professor, Vanderbilt University, Gastroenterology
1999-1999, Assistant Professor, Case Western Reserve University, Gastroenterology
1998-1999, Instructor, Case Western Reserve University, Gastroenterology
1993-1994, Postdoctoral fellow, Fred Hutchinson Cancer Research Center, Laboratory of D. Hockenbery, M.D., Molecular Biology
Methods and compositions for detecting cancers associated with methylation of hMLH1 promoter DNA, Patent Number: 6858388 B2, 2005, Institution, United States.
Screen for reactivation of MeCP2 on the inactive X chromosome identifies the BMP/TGF-β superfamily as a regulator of XIST expression.. Proceedings of the National Academy of Sciences of the United States of America.. 2017.
Transposon mutagenesis identifies candidate genes that cooperate with loss of Transforming Growth Factor-beta signaling in mouse intestinal neoplasms.. International journal of cancer. 140(4):853-863.. 2016.
Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation.. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(9):12477-12483.. 2016.
WRN promoter CpG island hypermethylation does not predict more favorable outcomes for metastatic colorectal cancer patients treated with irinotecan-based therapy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(18):4612-4622.. 2016.
Single cell lineage tracing reveals a role for TgfβR2 in intestinal stem cell dynamics and differentiation.. Proceedings of the National Academy of Sciences of the United States of America. 113(43):12192-12197.. 2016.
Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(11):1479-1485.. 2016.
A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus.. PLoS computational biology. 12(5):e1004919.. 2016.
Predicting Barrett's esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 25(5):727-735.. 2016.
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.. Clinical colorectal cancer. 15(2):164-169.. 2016.
Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas.. Molecular genetics & genomic medicine. 4(4):407-19.. 2016.
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.. Gastroenterology. 149(5):1204-.. 2015.
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015.
Actionable exomic incidental findings in 6503 participants: challenges of variant classification.. Genome research. 25(3):305-15.. 2015.
The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening.. Digestive diseases and sciences. 60(3):762-72.. 2015.
Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.. Gastroenterology clinics of North America. 44(2):473-489.. 2015.
Polymerase Slippage Restoration of Frameshifted TGFBR2 in Colorectal Cancer: A Novel Paradigm.. Gastroenterology. 148(7):1276-9.. 2015.
MethyLight Droplet Digital PCR for Detection and Absolute Quantification of Infrequently Methylated Alleles.. Epigenetics : official journal of the DNA Methylation Society.. 2015.
Molecular markers predictive of chemotherapy response in colorectal cancer.. Current gastroenterology reports. 17(2):431.. 2015.
Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 24(12):1890-1897.. 2015.
Colorectal cancer. Nature Reviews Disease Primers. :15065.. 2015.